Mylan announced the approval of its ANDA under 217076, though specific details regarding the drug substance and route are absent; a formal press release from the manufacturer will be issued on June 25, 2026, to provide further details. Market participants should await this announcement to fully assess the competitive dynamics and revenue implications for Mylan.